ION537

Preclinical and clinical investigations highlight the efficacy of diverse Hippo/YAP-targeted interventions, with recent clinical trials (e.g., VT3989, IK-930, IAG933, ION537) underscoring the translational promise of this pathway. Integrating cutting-edge insights into its regulatory networks and clinical targeting offers novel perspectives for precision oncology. By bridging fundamental discoveries with translational applications, this review establishes Hippo/YAP as a compelling therapeutic target and provides a theoretical foundation for developing innovative CRC therapies.

P1, N=15, Completed, Ionis Pharmaceuticals, Inc. | Recruiting --> Completed | N=102 --> 15 | Trial completion date: Jun 2023 --> Oct 2022 | Trial primary completion date: Jun 2023 --> Oct 2022